Sundry Photography/iStock Editorial via Getty Images Illumina’s (NASDAQ:ILMN) planned $7.1 billion purchase of cancer test developer Grail was sent back
Good morning. The proverbial consumer has become the central focus of the economy this summer, the key to deciphering the